Call Our Free Legal Helpline Anytime

or call

16 September 2015

Xarelto Lawsuits: By the Numbers

The anti-coagulant drug Xarelto (Rivaroxiban) is designed to prevent strokes and blood clots. A Xa inhibitor, the drug inhibits the production of a protein called thrombin, which is a component in the blood that allows the red blood cells to clump together, forming a blood clot.

This new generation blood thinner medication is prescribed for a range of different conditions, including deep vein thrombosis (also known as DVT), along with non-valvular atrial fibrillation, pulmonary embolism and it’s prescribed to prevent blood clots in patients who’ve recently undergone knee or hip replacement surgery.

Like most medications, there are a number of Xarelto side effects and complications, some of which can be potentially deadly, including blood clots, stroke, renal bleeding, brain hemorrhage, gastrointestinal bleeding, and even death.

The following is an overview of the various facts and figures that are sure to play a key role in the hundreds of Xarelto lawsuits which are currently moving forwards in the U.S. court system.

Xarelto Lawsuits: Relevant Facts and Figures

2011 –  Xarelto was approved by the U.S. Food and Drug Administration (FDA) on November 4, 2011.

10 mg, 15 mg and 20 mg – These are the three pill dosages of tablets that are currently available for Xarelto.

82 years – This is the average age of patients who experienced fatal Xarelto internal bleeding incidents according to a 2014 study.

75% – This is the percentage of non-fatal uncontrolled bleeding events that occurred in patients who were age 75 or older.

$3,000 – This is the average cost per patient for a one year course of Xarelto. Notably, the average per patient cost for a one year course of Warfarin/Coumadin — the so-called “industry standard” blood thinner drug that was used for many years prior to the release of Xarelto — is approximately $200.

50 years – This is the length of time that Warfarin/Coumadin was the sole and primary blood thinner drug on the American marketplace. Coumadin requires dietary restrictions and regular blood testing to ensure the drug is maintained at therapeutic levels in the patient’s system. Xarelto marketing touched upon this fact, presenting Xarelto as a safer and more convenient alternative medication — claims that many Xarelto lawsuit plaintiffs say were deceptive.

$10,000,000,000 – This is the current estimated value of the anti-coagulant drug market.

5 to 9 hours – This is the half-life of Xarelto in a healthy patient between the ages of 20 to 45. The half-life is the amount of time it takes for the body to process the drug to the point where just half the original dosage remains.

11 to 13 hours – This is the average Xarelto half-life in an elderly patient. Elderly patients who are not considered “healthy” may take even longer to process the drug.

0 – This is the number of antidotes and reversal agents that currently exist for Xarelto. Some Xarelto lawsuits criticize the manufacturer, claiming it was irresponsible to release a potentially deadly drug that lacks a reversal agent or antidote.

2013 – This is the year when the U.S. Food and Drug Administration issued a so-called black label warning due to the manufacturer’s alleged “downplaying” of the potential risks, Xarelto side effects and complications.

14,000 – This is the number of participants who were enrolled in the 2011 ROCKET-AF study, which compared Xarelto GI bleeding to the Warfarin internal bleeding risk. This Xarelto vs. Warfarin research revealed that Xarelto had a higher bleeding risk than Warfarin, but the latter had a higher rate of deadly GI bleeds.

8% – This was the risk of internal bleeding during the first 40 days of treatment, according to a study comparing Pradaxa and Xarelto.

4.8% – This was the risk of internal bleeding after the first 40 days of Xarelto treatment, according to the same study referenced above.

4x – A 2012 study with over 13,000 individuals revealed that the patients who received Xarelto after they underwent knee replacement or hip replacement surgery had a 4x higher risk of wound complications when compared to the other patients, who received heparin instead of Xarelto.

200% – Some studies revealed a 200% higher risk of bleeding when taking Xarelto instead of Warfarin/Coumadin.

MDL 2592 – Multi-district litigation case 2592 is currently moving forward in the U.S. District Court for the Eastern District of Louisiana under the control of Judge Eldon Fallon. A MDL is a grouping of very similar lawsuits, which are tried separately, although they share some pre-trial proceedings (such as hearings related to the discovery process) to save on manpower and time.

1230 – This is the total number of Xarelto lawsuits that have been compiled into MDL 2592 as of mid-August 2015. There were 500 cases as of June 2015. By July, there were over 800, reflecting a total of 430 new cases in the first half of August.

$650 million – This is the approximate sum of money that was paid out by the manufacturers of a similar new generation blood thinner drug, Pradaxa, settling approximately 4,000 legal claims.

August 2016 – This is when the first Xarelto lawsuit is scheduled to go to trial in the first of several Bellwether trials, which are trials that are designed to provide insight to individuals with similar cases.

Xarelto Lawsuits and You

If you or a loved one experienced serious Xarelto side effects like internal bleeding, a stroke, brain hemorrhage, blood clot or other symptoms, it’s possible that you could be eligible to receive financial compensation.

The experienced legal team at The Meldofsky Firm is passionate about providing legal services to clients who’ve experienced a loss. Our firm is now accepting new Xarelto lawsuits, so contact our legal professionals to discuss your case in a free evaluation session. Call The Meldofsky Firm today at 877-274-8672.

You may be eligible for financial compensation.

Name is required.
Email is required.
Phone is required.
Medical condition required.